https://sputnikglobe.com/20240316/ukraine-conducted-experiments-on-patients-in-mariupol-testing-western-carcinogenic-drug---docs-show-1117357778.html
Ukraine Conducted Experiments on Patients in Mariupol Testing Western Carcinogenic Drug - Docs Show
Ukraine Conducted Experiments on Patients in Mariupol Testing Western Carcinogenic Drug - Docs Show
Sputnik International
Patients in the psychiatric ward of Mariupol Hospital No. 7 were not informed that a drug for rheumatoid arthritis, tested on them could potentially contribute to the growth of malignant tumors of the lymphatic and hematologic systems, documents obtained by Sputnik showed on Saturday.
2024-03-16T03:50+0000
2024-03-16T03:50+0000
2024-03-16T03:50+0000
world
biolab
ukrainian crisis
ukrainian conflict
ukraine crisis
biowarfare
cancer
mariupol
ukraine
russia
https://cdn1.img.sputnikglobe.com/img/07e8/03/10/1117357919_0:160:3072:1888_1920x0_80_0_0_eaede3581c005c29147dc4609d0e9d3c.jpg
The drug was tested at the commission of Western companies with the assistance of Ukrainian officials.The documents were found in the hospital basement during reconstruction works. They mainly outlined the tests of experimental drug SB4, which suppresses the action of molecules called tumor necrosis factor alpha (TNF-α) that plays an important role in the immune system and is associated with inflammation in the joints. However, impaired biological functions of TNF-α are also known to contribute to the development of malignant tumors. SB4 is produced by a number of pharmaceutical companies, including Biogen Idec Denmark Manufacturing ApS, Belgium's Catalent Pharma Solutions and Fisher Clinical Services UK Limited. South Korean biopharmaceutical giant Samsung Bioepis sponsored the tests. The documents include an investigator's brochure on SB4 in English, printed by Samsung Bioepis and marked as confidential. It said, among other things, that a "possible risk for the development of lymphomas, leukemia or other haematopoietic or solid malignancies in patients treated with a TNF-antagonist cannot be excluded." Children, adolescents, and young adults up to 22 years of age treated with a TNF-α antagonist were also reported to be prone to malignancies, sometimes fatal. Other tumors potentially caused by the substance include melanoma and non-melanoma skin cancer, according to the brochure. Among the documents was also a study protocol SB4-G31-RA dated November 2013, which contained the text of the information sheet and consent form offered to experimental patients in Ukrainian and Russian. In terms of possible cancer-inducing side effects, it only mentioned that "in rare cases," up to one per 1,000 patients, another TNF-α antagonist drug, Enbrel, caused skin cancer. The documents were compiled between 2008 and 2016. Among other things, they show that drugs were also tested on infants under the age of one year. The findings also included boxes with numerous envelopes from logistics companies and containers for biological materials with recipient addresses in laboratories in Switzerland, the UK, and the US.
https://sputnikglobe.com/20230413/chilling-and-frightening-us-bioweapons-in-ukraine-pose-massive-risks-1109463019.html
https://sputnikglobe.com/20230412/us-working-on-universal-genetically-engineered-bioweapon-russian-parliamentary-investigation-1109381193.html
mariupol
ukraine
russia
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
2024
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
News
en_EN
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
us defense department, ukrainian biolab, us biolabs in ukraine, us biological weapons program, us biological weapons program, u.s. biological weapons program, biological threat reduction program locations, russia special military operation, russia-nato showdown, biological warfare, russian defense ministry, ukrainian labs, artificial diseases, us bio-research, american bioweapon, american biolabs, biowarfare, bioterrorism, biological threat, artificial infection, bioprogram, bioresearch, biohazard
us defense department, ukrainian biolab, us biolabs in ukraine, us biological weapons program, us biological weapons program, u.s. biological weapons program, biological threat reduction program locations, russia special military operation, russia-nato showdown, biological warfare, russian defense ministry, ukrainian labs, artificial diseases, us bio-research, american bioweapon, american biolabs, biowarfare, bioterrorism, biological threat, artificial infection, bioprogram, bioresearch, biohazard
Ukraine Conducted Experiments on Patients in Mariupol Testing Western Carcinogenic Drug - Docs Show
MARIUPOL (Sputnik) - Patients in the psychiatric ward of Mariupol Hospital No. 7 were not informed that a drug for rheumatoid arthritis, tested on them could potentially contribute to the growth of malignant tumors of the lymphatic and hematologic systems, documents obtained by Sputnik showed on Saturday.
The drug was tested at the commission of Western companies with the assistance of Ukrainian officials.
The documents were found in the hospital basement during reconstruction works. They mainly outlined the tests of experimental drug SB4, which suppresses the action of molecules called tumor necrosis factor alpha (TNF-α) that plays an important role in the immune system and is associated with inflammation in the joints. However, impaired biological functions of TNF-α are also known to contribute to the development of malignant tumors.
SB4 is produced by a number of pharmaceutical companies, including Biogen Idec Denmark Manufacturing ApS, Belgium's Catalent Pharma Solutions and Fisher Clinical Services UK Limited. South Korean biopharmaceutical giant Samsung Bioepis sponsored the tests.
The documents include an investigator's brochure on SB4 in English, printed by Samsung Bioepis and marked as confidential. It said, among other things, that a "possible risk for the development of lymphomas, leukemia or other haematopoietic or solid malignancies in patients treated with a TNF-antagonist cannot be excluded." Children, adolescents, and young adults up to 22 years of age treated with a TNF-α antagonist were also reported to be prone to malignancies, sometimes fatal. Other tumors potentially caused by the substance include melanoma and non-melanoma skin cancer, according to the brochure.
Among the documents was also a study protocol SB4-G31-RA dated November 2013, which contained the text of the information sheet and consent form offered to experimental patients in Ukrainian and Russian. In terms of possible cancer-inducing side effects, it only mentioned that "in rare cases," up to one per 1,000 patients, another TNF-α antagonist drug, Enbrel, caused skin cancer.
The documents were compiled between 2008 and 2016. Among other things, they show that drugs were also tested on infants under the age of one year.
The findings also included boxes with numerous envelopes from logistics companies and containers for biological materials with recipient addresses in laboratories in Switzerland, the UK, and the US.
